Annals of Indian Academy of Neurology
  Users Online: 1030 Home | About the Journal | InstructionsCurrent Issue | Back IssuesLogin      Print this page Email this page  Small font size Default font size Increase font size


 
Table of Contents
CASE REPORT
Year : 2015  |  Volume : 18  |  Issue : 5  |  Page : 56-58
 

Multisystem involvement in neuromyelitis optica


Division of Neurology, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California, USA

Date of Submission26-Oct-2014
Date of Decision12-Jan-2015
Date of Acceptance22-Jan-2015
Date of Web Publication11-Sep-2015

Correspondence Address:
Jay Desai
4650 Sunset Boulevard # 82, Los Angeles, California 90027
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-2327.164830

Rights and Permissions

 

   Abstract 

We describe a case of pediatric neuromyelitis optica (NMO) with muscle and lung involvement in addition to central nervous system disease. Our patient initially presented with features of area postrema syndrome, then subsequently with optic neuritis. The patient also had recurrent hyperCKemia that responded to corticosteroids. Finally, axillary and hilar adenopathy with pulmonary consolidation were noted as well and responded to immunomodulation. Our case highlights multisystem involvement in NMO including non-infectious pulmonary findings which have not been described in the pediatric population previously.


Keywords: Adenopathy, hyperCKemia, lung consolidation, neuromyelitis optica, NMO


How to cite this article:
Langille MM, Desai J. Multisystem involvement in neuromyelitis optica. Ann Indian Acad Neurol 2015;18, Suppl S1:56-8

How to cite this URL:
Langille MM, Desai J. Multisystem involvement in neuromyelitis optica. Ann Indian Acad Neurol [serial online] 2015 [cited 2018 Apr 20];18, Suppl S1:56-8. Available from: http://www.annalsofian.org/text.asp?2015/18/5/56/164830



   Case Report Top


A 13-year-old girl initially presented with nausea and intractable vomiting for several weeks associated with unintentional weight loss of about 22 pounds. She subsequently developed cranial nerve palsies and a magnetic resonance imaging (MRI) of the brain showed T2 hyperintensity in the right medulla extending to the cervicomedullarly junction as well as in the anterior medial temporal lobe [Figure 1]. She had elevation of multiple muscle inflammatory markers; creatine kinase (CK) to 5,018, lactate dehydrogenace (LDH) to 1000, and aldolase to 23. She was given methylprednisolone pulse and intravenous immunoglobulin. She showed overall clinical improvement and CK level normalized. She was readmitted 4 months later with blindness due to left-sided optic neuritis. Her CK was now elevated to 8,216. MRI of femur showed patchy T2 hyperintensities and enhancement within the peripheral right and left biceps femoris muscle and left adductor magnus muscle suggestive of myositis [Figure 2]. She had a chest X-ray that showed left lower lobe consolidation and hilar adenopathy. Computed tomography scan of the chest confirmed left lower lobe consolidation [Figure 3] and left hilar adenopathy plus showed bilateral axillary adenopathy. Tuberculosis and other infections were ruled out after extensive investigations and consultation with infectious disease specialists. Extensive rheumatological investigations including antinuclear antibodies, anti-neutrophil cytoplasmic antibodies, anti-Sjogren's syndrome antibodies A and B, complement levels were all negative. Serum and cerebrospinal fluid angiotensin-converting enzymes were normal. Rheumatological diseases were considered unlikely after consultation with pediatric rheumatologists. Antibodies to aquaporin-4 (AQP-4) were positive in the serum but negative in cerebrospinal fluid. She was treated with methylprednisolone pulse followed by rituximab with a second cycle about 6 months later. Her CK level normalized quickly, vision showed slow improvement to 20/80 and a chest X-ray subsequently normalized. Antibodies to AQP-4 were reconfirmed several months later to be positive. She has remained stable overall for almost 1 year since the episode of optic neuritis.
Figure 1: T2 hyperintensity in medulla of our patient who initially had features of area postrema syndrome

Click here to view
Figure 2: Abnormal area of enhancement in left adductor magnus muscle during an episode of hyperCKemia

Click here to view
Figure 3: Left lower lobe consolidation

Click here to view



   Discussion Top


Neuromyelitis optica (NMO) was first recognized as a distinct clinical entity in the nineteenth century. [1] Subsequently, Devic and his student Gault used the term "neuromyelitis optica" for the first time. [2],[3] Since then, there have been significant advances in our understanding of this condition especially with the availability of the highly specific testing for the AQP-4 antibodies in 2004. [4] Previously, absence of disease other than in the optic nerves and the spinal cord was considered necessary for a diagnosis of NMO. However, revised diagnostic criteria in 2006 concluded that involvement of the central nervous system beyond the optic nerves and spinal cord was compatible with NMO. [5] Those criteria were further revised this year and include recognized core features of NMO spectrum disorders (NMOSD): Optic neuritis, myelitis, area postrema syndrome (nausea, vomiting, and hiccups), diencephalic syndrome, and other brainstem and cerebral syndromes. The expansion of the criteria are aimed at facilitating diagnosis in seronegative patients with corresponding MRI abnormalities with dissemination in time as well as optic neuritis, myelitis, or area postrema syndrome plus another core feature. [6]

AQPs are water channels and are expressed in highest concentration in opticospinal tissue. Development of optic nerve and spinal cord lesions in NMO and NMOSD is thought to be secondary to complement activation by antibodies to AQP-4, resulting in perivascular immune complex deposition and astrocyte injury. AQPs are also expressed in tissues throughout the body in addition to the central nervous system including in various epithelia and endothelia involved in fluid transport, as well as in other cell types such as epidermis, adipocytes, and skeletal muscle. [7] They are also expressed in lung and airways. [8] In recent years, clinical involvement of tissues other than the central nervous system is increasingly recognized with NMO and NMOSD. Various cases of transient hyperCKemia have been reported in recent years suggesting active muscle disease in NMO. [9-15] Inflammatory changes have been reported in some of these patients. Reduced AQP-4 expression and deposition of activated complement has been noted and complement-mediated sarcolemmal injury is hypothesized to be the reason for hyperCKemia. [12],[15]

Non-infectious lung involvement in NMO has been described in a single case report previously with lung infiltrate and adenopathy. [16] Biopsy of a lymph node in this 50-year-old patient revealed non-caseating granuloma and the authors suspected co-existence of sarcoidosis with NMO. There is significant interest in co-occurrence and overlap of rheumatological disease, NMO, and sarcoidosis and in fact all of these are often considered to be on a single spectrum of disorders. [17],[18] The limitation of this case is that we did not perform a biopsy in our patient because of relatively quick resolution with corticosteroids and immunomodulation. It is possible that our patient may have had co-existent sarcoidosis. However, our case highlights multisystem involvement in pediatric NMO, NMOSD, and overlap with other related disorders like sarcoidosis. Pulmonary involvement in NMO and NMOSD is supported by the fact that AQPs are also expressed in lung and airways.


   Acknowledgement Top


Authors would like to thank Dr. Skorn Ponrartana for providing help with figures.

 
   References Top

1.
Jarius S, Wildemann B. On the contribution of Thomas Clifford Allbutt, F.R.S., to the early history of neuromyelitis optica. J Neurol 2013;260:100-4.  Back to cited text no. 1
    
2.
Gault F. The neuromyelitis optica. Thesis presented to Faculty of Medicine and Pharmacy in Lyon. 1894.  Back to cited text no. 2
    
3.
Devic E. Myelitesubaiguecompliquee de neuriteoptique. Bull Med 1894;8:1033-4.  Back to cited text no. 3
    
4.
Lennon VA, Wingerchuk DM, Kryzer TJ. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004;364:2106-12.  Back to cited text no. 4
    
5.
Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-9.  Back to cited text no. 5
    
6.
Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll W, Chitnis T, et al. Revised Diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2014;82:10.  Back to cited text no. 6
    
7.
Verkman AS. Aquaporins in clinical medicine. Annu Rev Med 2012;63:303-16.  Back to cited text no. 7
    
8.
Verkman AS. Role of aquaporins in lung liquid physiology. Respir Physiol Neurobiol 2007;159:324-30.  Back to cited text no. 8
    
9.
Suzuki N, Takahashi T, Aoki M, Misu T, Konohana S, Okumura T, et al. Neuromyelitis optica preceded by hyperCKemia episode. Neurology 2010;74:1543-5.  Back to cited text no. 9
    
10.
Deguchi S, Deguchi K, Sato K, Yunoki T, Omote Y, Morimoto N, et al. HyperCKemia related to the initial and recurrent attacks of neuromyelitis optica. Intern Med 2012;51:2617-20.  Back to cited text no. 10
    
11.
Okada H, Wada M, Sato H, Yamaguchi Y, Tanji H, Kurokawa K, et al. Neuromyelitisoptica preceded by hyperCKemia and a possible association with coxsackie virus group A10 infection. Intern Med 2013;52:2665-8.  Back to cited text no. 11
    
12.
Malik R, Lewis A, Cree BA, Ratelade J, Rossi A, Verkman AS, et al. Transient hyperCKemia in the setting of neuromyelitisoptica (NMO). Muscle Nerve 2014;50:859-62.  Back to cited text no. 12
    
13.
Di Filippo M, Franciotta D, Massa R, Di Gregorio M, Zardini E, Gastaldi M, et al. Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitisoptica. Neurology 2012;79:1182-4.  Back to cited text no. 13
    
14.
Yokoyama N, Niino M, Takahashi T, Matsushima M, Maruo Y. Seroconversion of neuromyelitisoptica spectrum disorder with hyperCKemia: A case report. Eur J Neurol 2012;19:e143.  Back to cited text no. 14
    
15.
Guo Y, Lennon VA, Popescu BF, Grouse CK, Topel J, Milone M, et al. Autoimmune Aquaporin-4 Myopathy in Neuromyelitis optica spectrum. JAMA Neurol 2014;71:1025-9.  Back to cited text no. 15
    
16.
Sawaya R, Radwan W. Sarcoidosis associated with neuromyelitis optica. J Clin Neurosci 2013;20:1156-8.  Back to cited text no. 16
    
17.
Wingerchuk DM, Weinshenker BG. The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 2012;18:5-10.  Back to cited text no. 17
    
18.
Enzenauer RJ, West SG. Sarcoidosis in autoimmune disease. Semin Arthritis Rheum 1992;22:1-17.  Back to cited text no. 18
    


    Figures

  [Figure 1], [Figure 2], [Figure 3]



 

Top
Print this article  Email this article

    

 
   Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (620 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Case Report
   Discussion
   Acknowledgement
    References
    Article Figures

 Article Access Statistics
    Viewed1019    
    Printed16    
    Emailed0    
    PDF Downloaded66    
    Comments [Add]    

Recommend this journal